Start here if you're new
what it is
MeiraGTx makes gene therapies, which are one-time genetic fixes for serious diseases.
how it gets paid
Last year Meiragtx made $33M in revenue. Inherited retinal disease programs was the main engine at $12M, or 36% of sales.
what just happened
Revenue hit $6M, while EPS stayed deep red at -$1.61.
At a glance
B balance sheet — gets the job done, barely
45/100 earnings predictability — expect surprises
-$2.12 fy2024 eps est
$33M fy2024 rev est
n/a operating margin
xvary composite: 48/100 — below average
What they do
MeiraGTx makes gene therapies, which are one-time genetic fixes for serious diseases.
MeiraGTx has five programs in clinical development and three core disease areas. That spread matters because you are not betting on one shot. Its viral vector design and manufacturing, which means the delivery vehicles for genes are built in-house, so your supply chain does not depend on outsiders.
How they make money
$33M
annual revenue
Inherited retinal disease programs
$12M
Neurodegenerative disease programs
$8M
Xerostomia and xerophthalmia programs
$7M
Platform licensing and manufacturing
$6M
The products that matter
partner-funded revenue stream
Collaboration Revenue
$27.4M · 83% of revenue
this was $27.4M of a $33M revenue base. Most of the income on this page came from partners, not product demand.
current funding
clinical development engine
Gene Therapy Pipeline
$475M potential deal value
the pipeline is the whole equity story. A collaboration with Eli Lilly worth up to $475M shows outside interest, but the stock still needs clinical proof.
main catalyst
liquidity for trials
Cash & Equivalents
$142.5M
cash is a product category in pre-commercial biotech. Against a $35.2M quarterly net loss, it tells you how much room management has to wait for data.
runway
Key numbers
$33M
annual revenue
This is the whole top line. You are buying a $595M company on a $33M sales base.
-$2.12
fy2024 eps
Losses are still the norm. Every share is losing money instead of sending it back to you.
-493.4%
operating margin
For every $1 of sales, the business lost about $4.93. That is what a pre-approval biotech looks like.
$12M
long-term debt
The balance sheet is not loaded with debt. That gives the company some room while the pipeline works.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 10 / 100
- long-term debt $12M (2% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for MGTX right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Revenue hit $6M, while EPS stayed deep red at -$1.61.
Revenue rose 1,370% vs. prior year, but the company still posted a big loss. That is the whole story in one line: more sales, still no profit.
$6M
revenue
-$1.61
eps
n/a
n/a
the number that mattered
Revenue jumped 1,370% to $6M. The starting point was tiny, and the business is still losing money.
source: company earnings report, 2025
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is lead program clinical failure. If the data disappoint, the whole $595M valuation loses its center of gravity.
high
lead gene therapy data miss
This is a pipeline-first stock. If the lead readout fails to support the science, the stock loses the reason investors tolerate losses and thin revenue.
impact: it puts the $595M market value on weaker footing fast
high
cash burn shortens the runway
$142.5M in cash looks decent until you put it next to a $35.2M quarterly net loss. If timelines slip, financing risk moves from background noise to main event.
impact: new capital becomes more likely, and existing holders carry the dilution risk
med
partner dependence cuts both ways
Collaboration revenue was $27.4M of the $33M total. When 83% of revenue comes from partners, milestone timing and partner priorities hit the income statement fast.
impact: revenue quality stays lumpy even before you get to clinical risk
With $142.5M in cash, a $35.2M quarterly net loss, and 83% of revenue tied to collaboration payments, you are underwriting science, timing, and financing at the same time.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
next company update
Use the next update to judge whether management bought more time or spent more of it. Last full review: updated mar 13, 2026.
runway
cash versus quarterly loss
$142.5M in cash against a $35.2M quarterly net loss is the trend that matters most. If that gap narrows the wrong way, the story gets more expensive.
clinical
lead program readouts
This stock will not earn its valuation through steady execution. It needs useful data. Watch the trial timeline before you watch the chart.
revenue quality
collaboration share of revenue
Collaboration revenue was 83% of the total. If that share falls without a stronger funding source or cleaner clinical progress, the pressure shifts back to financing.
Analyst rankings
short-term outlook
mixed
target data are thin here. in human-speak: there is no clean consensus to hide behind.
risk profile
volatile
a 1.5 beta and 10 / 100 price stability tell you this stock swings harder than the market.
chart momentum
catalyst-led
this chart is a scoreboard for trial updates and financing expectations, not a smooth operating trend.
earnings predictability
45/100
when revenue depends on milestones and grants, clean quarter-to-quarter predictability is not part of the package.
source: institutional data
Institutional activity
institutional ownership data for MGTX is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$8
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive